Chemical Engineering Magazine has published its second article of the biopharmaceutical manufacturing series, written by Biomanufacturing Engineer, David Gemmell. In the article he explores how chemical engineers play their part in the manufacture of biopharma products from traditional vaccines to new modalities such as mRNA-based therapeutics.
Learn more about modern manufacturing philosophies in the second article of the series, Biopharmaceutical Manufacturing: An Evolving Industry.
David Gemmell has been working for
for over six years. David is currently employed with the Technical & Scientific Solutions MSAT (Manufacturing Sciences & Technology) department. David’s primary focus is on optimising or troubleshooting downstream purification unit operations for customers, focusing on both novel and traditional modalities, across all purification technologies. He is also the High Temperature Short Time Subject Matter Expert for upstream viral risk mitigation. At University David obtained a BEng (Hons) in Chemical Engineering and an MSc in Advanced Chemical & Process Engineering. His early career was based in the nuclear and power generation sectors before moving into biopharmaceutical and life sciences.
Creating Bottlenecks in Europe; Opportunities for Production Staff BioPlan Associates, Inc. Hiring of bioprocessing professionals has remained a…
As an early-stage or small-sized biotech company, you need to move fast and be nimble. Success is measured…
One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …
The development and implementation of analytical methods are essential for success at all phases of a molecule’s journey,…
